QPS Austria GMBH
- UEI
- V615KLQ23YA5
- CAGE
- 3613N
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Website
- qps.com
- Founded
- 1995
- Employees
- 251-1K
- Estimated annual revenue
- $100M-$250M
- Industry
-
- Industrials
- Commercial & Professional Services
- Professional Services
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Experimental validation of candidate alzheimer's disease treatments identified by multi-omics analyses | National Institute on Drug Abuse | $830,053 | |
| In vivo efficacy studies of a candidate alzheimer treatment in a transgenic mouse model | National Institute on Drug Abuse | $199,812 | |
| Phenotypic screening of candidate drugs to treat alzheimers disease | National Institute on Drug Abuse | $298,624 | |
| Feasibility study for an invivo project using age matched transgenic mice. | Veterans Integrated Service Network 2 | $25,000 |
About QPS Austria GMBH
QPS Austria GMBH is a contract research organization that provides specialized services to support Alzheimer's disease research for the U.S. federal government. The company, registered to receive federal awards since May 2009, focuses on experimental validation of candidate Alzheimer's disease treatments identified through multi-omics analyses. As a for-profit limited liability company, QPS Austria GMBH has established itself as a key partner in the National Institute on Aging's efforts to advance Alzheimer's research and drug development.
The primary services provided by QPS Austria GMBH involve conducting in vivo studies using transgenic Alzheimer's disease mouse models to evaluate the efficacy and tolerability of potential treatments. These studies include pharmacodynamic assessments, testing of novel drug formulations, and phenotypic screening of FDA-approved drugs that may be repurposed for Alzheimer's treatment. The company has received multiple contract awards from the National Institute on Aging, a component of the National Institutes of Health within the Department of Health and Human Services. These awards, typically structured as firm fixed price purchase orders or delivery orders, range in value from approximately $200,000 to $858,000. The work supports various research initiatives, including the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study and experimental validation of treatments identified through multi-omics analyses. Notably, none of the contracts awarded to QPS Austria GMBH have set-aside designations.
QPS Austria GMBH holds a single-award Indefinite Delivery Contract (IDC) with the National Institute on Aging, awarded on June 1, 2022, with a ceiling value of $2,326,159.08 and a performance period through May 31, 2025. This IDC focuses on the experimental validation of candidate Alzheimer's disease treatments identified through multi-omics analyses. Under this vehicle, the National Institute on Aging has issued multiple firm fixed price delivery orders to QPS Austria GMBH. These orders, valued at $638,000 and $830,053 respectively, require the company to conduct testing of candidate treatments in transgenic mouse models to assess their effects on Alzheimer's disease pathology and progression. The work is performed in Austria and supports the National Institute on Aging's ongoing efforts to identify effective treatments for Alzheimer's disease.
Quick answers
What is QPS Austria GMBH's UEI?
QPS Austria GMBH's Unique Entity ID (UEI) in SAM.gov is V615KLQ23YA5.
What is QPS Austria GMBH's CAGE code?
QPS Austria GMBH's CAGE code is 3613N.
What is QPS Austria GMBH's primary NAICS code?
QPS Austria GMBH's primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Is QPS Austria GMBH registered in SAM.gov?
QPS Austria GMBH's SAM.gov registration expired on September 11, 2024.
What is QPS Austria GMBH's most recent federal award?
QPS Austria GMBH's most recent federal contract award is Experimental validation of candidate alzheimer's disease treatments identified by multi-omics analyses (75N95023F00001), from National Institute on Drug Abuse, on June 1, 2023.
On GovTribe
See QPS Austria GMBH's full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors